PARPi	Clinical Trial (ClinicalTrial.gov no.)	Design	Setting	Patient population	Primary outcome measure	Total patients (n)	Intervention	Key results
Olaparib	OlympiAD (NCT02000622)[@253755]	Olaparib vs PCT (double-blind RCT)	Advanced/Metastatic	Advanced/Metastatic gBRCA HER2-, ≤2 prior lines	Investigator-assessed PFS	302	Olaparib (n=205), PCT (n=97)	Median PFS was 7.0 months in the olaparib group vs 4.2 months in the PCT group (HR: 0.58 [95% CI: 0.43−0.80]; p<0.001)
	OlympiA (NCT02032823)[@253712]	Olaparib vs placebo (double-blind RCT)	Adjuvant	Early-stage gBRCA HER2-, post-completion SoC adjuvant therapy	IDFS	1836	Olaparib (n=921), placebo (n=915)	At a median follow-up of 2.5 years, the 3-year IDFS was 85.9% in the olaparib group and 77.1% in the placebo group (difference, 8.8 % points [95% CI: 4.5−13.0]; HR: 0.58 [99.5% CI: 0.41−0.82; p<0.001)
	PARTNER (NCT03150576)	C+P+Olaparib (open-label, single-arm)	Neoadjuvant	TNBC and/or gBRCA	pCR rates at surgery after neoadjuvant chemotherapy +/- olaparib	Recruiting (no results available)
	LUCY (NCT03286842)[@253756]	Olaparib (open-label, single arm)	Metastatic	Metastatic, gBRCA HER2-, ≤2 prior lines	Investigator-assessed PFS in a real-world setting (interim analysis after 160 PFS events)	252	Olaparib (n=252)	At the interim analysis, the median PFS was 8.11 months (95% CI: 6.93−8.67; 166/252 events; 65.9% maturity)
Talazoparib	EMBRACA (NCT01945775)[@253757]	Talazoparib vs PCT (double-blind, RCT)	Advanced/Metastatic	Advanced/Metastatic gBRCA, ≤3 prior lines	Investigator-assessed PFS	431	Talazoparib group (n=287), PCT (capecitabine, eribulin, gemcitabine, or vinorelbine) group (n=144)	Median PFS was 8.6 months in the talazoparib group vs 5.6 months in the PCT group (HR: 0.54 [95% CI 0.41−0.71]; p<0.001)
Niraparib	BRAVO (NCT01905592)[@253758]	Niraparib vs PCT (double-blind RCT)	Advanced/Metastatic	Advanced/Metastatic gBRCA HER2-, ≤2 prior lines	Investigator-assessed PFS	206 ITT	Niraparib (n=141), PCT (n=74)	At a median follow-up of 19.9 months, median PFS was 4.1 months in the niraparib vs 3.1 months in the PCT group (HR: 0.96 [95% CI: 0.65−1.44]; p=0.86)
	ZEST (NCT04915755)	Niraparib vs placebo (double-blind RCT)	Stage I to III (Early to Advanced)	BRCA-mutated HER2- (independent of hormone receptor status, including hormone receptor-positive and TNBC); and BRCA-wildtype TNBC	DFS	Recruiting (no results available)
Veliparib	BROCADE 3 (NCT02163694)	C+P+V vs C+P+ placebo (double-blind RCT)	Advanced/Metastatic	Metastatic gBRCA HER2-, 0─2 prior lines	Investigator-assessed PFS per RECIST (v 1.1)	509 ITT	Veliparib group (n=337), placebo group (n=172)	Median PFS was 14.5 months (95% CI: 12.5–17.7) in the veliparib group vs 12.6 months (95% CI: 10.6–14.4) in the control group (HR: 0.71 [95% CI: 0.57–0.88]; p=0.0016)
	BrighTNess (NCT02032277)[@253759; @253760]	PCV vs PC+placebo vs P+placebo+placebo; plus AC (double-blind, RCT)	Neoadjuvant	Neoadjuvant TNBC gBRCA	pCR in breast and lymph nodes	634	PCV (n=316), PC (n=160) and P (n=158)	pCR in the PCV group vs P alone (53% vs 31%; p<0.0001) vs PC (58%; p=0.36).[@253759] At a median follow-up of 4.5 years, HR for EFS with PCV vs P was 0.63 (95% CI: 0.43‒0.92, p=0.016) and 1.12 (95% CI: 0.72‒1.72; p=0.620) for PCV vs PC.[@253760]